29LOW

ACR

ACRUX FPO [ACR]
Acrux Limited, together with its subsidiaries, develops and commercializes generic and topically applied pharmaceutical products in Australia, Europe, the United States, and internationally. The company provides estradiol transdermal sprays to women for the treatment of flushes associated with menopause under the Evamist and Lenzetto brand names; Dapsone 5% and Dapsone 7.5%, which are gels for the treatment of acne vulgaris; and Lidocaine and Prilocaine Cream USP, a topical anesthetic cream. It is also involved in the development of Efinaconazole, a topical solution used to treat fungal infections of toenails; Nitroglycerin 0.4%, an ointment for the treatment of pain associated with chronic anal fissure; and Acyclovir 5%, a cream for the treatment of cold sores. The company was incorporated in 1998 and is based in West Melbourne, Australia.
Healthcare · ASX Small Cap
$0.0130 +8.3%

Updated 13 Mar 2026 · Scores refresh every scan

⚠ Funding Risk — Cash runway under 4 quarters. Capital raise or funding may be required.

Score Breakdown

Technical41
Catalyst53
Sentiment50
Fundamental36
Momentum42
Risk Gate24

Active Signals

Bullish Signals

  • Volatility expanding rapidly (choppy)
  • Critical cash runway (1.6 quarters)
  • 4C filed 2026-01-28
  • Low P/S ratio (1.9x)
  • Strong revenue growth (+1350%)
  • EPS estimates revised downward (-10pts)
  • Near 52-week low (7% of range)
  • Micro-cap ($5-20M) - high risk
  • CANSLIM I: Institutional ownership (11%)
  • Strong revenue momentum (+1350%)
  • Altman Z-Score distress zone (0.74 < 1.81, low-confidence approx)
  • Penny stock risk ($0.013)
  • Beneish M-Score 0.48 > -1.78: likely earnings manipulation
  • RBA hiking (-3pts)
  • Overseas risk_off (-3pts, S&P500 down, VIX 27)

Risk Signals

  • Negative 5-day momentum (-3.7%)
  • Below 200-day MA (long-term downtrend)
  • Deeply negative margins (-84%)
  • Insufficient sentiment data (defaulting to neutral)
  • Neutral/mixed sentiment
  • Negative 12-1 momentum (-42%)
  • Volume-weighted momentum negative (-2.58%/day)

Recent Catalysts

NONE Acrux receives $0.55m advance on FY26 R&D Tax Incentive
NONE Notification of cessation of securities - ACR
NONE Half Yearly Report and Accounts
LOW Quarterly Activities/Appendix 4C Cash Flow Report
Announcement tone +3pts

Recent ASX Announcements

2026-03-11 Acrux receives $0.55m advance on FY26 R&D Tax Incentive PRICE SENSITIVE
2026-02-25 Notification of cessation of securities - ACR
2026-02-24 Half Yearly Report and Accounts PRICE SENSITIVE
2026-01-28 Quarterly Activities/Appendix 4C Cash Flow Report PRICE SENSITIVE

Key Metrics

$5.3M
Market Cap
247K
Avg Volume
1.0x
Vol Ratio
$0.01 — $0.03
52-Week Range
N/A
Short Interest
2 qtrs
Cash Runway
-102.2%
ROE
-83.8%
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: 0%
AAnnual EarningsfailCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandneutralFloat: 71%
LLeader vs LaggardlaggardRS: -10
IInstitutional SponsorshippassInst: 11%
MMarket DirectionneutralNeutral

Sector: Healthcare

Ranked #104 of 116 · Sector avg: 36

View all Healthcare signals →
Related Tickers
EMV 53NYR 52PNV 48NXN 48SDI 48

Sign up free to unlock ACR analysis

Score breakdowns, signals, catalysts, and full analysis for 2,200+ ASX small caps. 30-day free Pro trial included.

No credit card required. Unsubscribe anytime.
Already have access? Log in